Details for New Drug Application (NDA): 203631
✉ Email this page to a colleague
NDA 203631 describes SODIUM OXYBATE, which is a drug marketed by Amneal, Ascent Pharms Inc, and Hikma, and is included in three NDAs. It is available from one supplier. Additional details are available on the SODIUM OXYBATE profile page.
The generic ingredient in SODIUM OXYBATE is sodium oxybate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the sodium oxybate profile page.
The generic ingredient in SODIUM OXYBATE is sodium oxybate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the sodium oxybate profile page.
Summary for 203631
| Tradename: | SODIUM OXYBATE |
| Applicant: | Amneal |
| Ingredient: | sodium oxybate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 203631
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SODIUM OXYBATE | sodium oxybate | SOLUTION;ORAL | 203631 | ANDA | Amneal Pharmaceuticals LLC | 65162-065 | 65162-065-87 | 1 BOTTLE in 1 CARTON (65162-065-87) / 180 mL in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 0.5GM/ML | ||||
| Approval Date: | Sep 10, 2025 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
